论文部分内容阅读
目的探讨纤溶酶用于治疗脑血栓的效果。方法收集2009年1月至2010年12月期间在我科室就诊的的160例患者,将其随机分成治疗组与对照组。对照组用巴曲酶静脉注射,治疗组用纤溶酶静脉注射。在治疗前与治疗后的第一天和第一周的时候分别对治疗组和对照组患者进行临床疗效比较,并且测定出凝血时间、血小板、血糖及血浆蛋白原含量,同时观察其他不良反应及出血倾向。结果治疗组与对照组的临床评分和治疗效果相近,没有明显差异,无统计学意义(P>0.05),而且纤溶酶治疗急性脑血栓无不良反应出现,安全可靠。结论纤溶酶与巴曲酶在治疗急性脑血栓方面疗效相近,安全更高。
Objective To investigate the effect of plasmin on cerebral thrombosis. Methods A total of 160 patients from our hospital from January 2009 to December 2010 were collected and randomly divided into treatment group and control group. Control group with batroxobin intravenous injection, the treatment group with intravenous injection of plasmin. Before treatment and after treatment on the first day and the first week when the treatment group and control group were compared the clinical efficacy and determination of clotting time, platelets, blood glucose and plasma protein content, while observing other adverse reactions and Bleeding tendency. Results There was no significant difference between the treatment group and the control group in clinical score and treatment effect, and there was no significant difference (P> 0.05). There was no adverse reaction in the treatment of acute cerebral thrombosis with plasmin, which was safe and reliable. Conclusion The efficacy of plasmin and batroxobin in the treatment of acute cerebral thrombosis is similar and safe.